Author name: TB Alliance

Drug company sees funding research to combat dengue and tuberculosis as corporate goodwill–and good business Singapore–Swiss drug giant Novartis is

Novartis AG has launched its Novartis Institute for Tropical Diseases (NITD) in Singapore with a two-day symposium. Dr. Paul Herrling,

TROPICAL fevers often leave their victims running hot and cold. Critics of the pharmaceutical industry argue that drugmakers behave in

The Alliance is convening a core group of leading scientists after this week’s Keystone meeting on TB Genomics to assess

The Global Alliance for TB Drug Development (TB Alliance) applauds yesterday’s announcement from Gates Foundation to establish the Grand Challenges

Today’s most urgent global public health crises – the alarming progress of AIDS, tuberculosis, and malaria – confront our medical

Bay Area biotech leaders are in the forefront of a movement to teach our profit-driven drug development industry how to

Two stakeholders of the TB Alliance are partnering to establish a South African Clinical Trials Consortium with an emphasis on

The TB Alliance Stakeholders Meeting was held in conjunction with the annual International Union Against Tuberculosis and Lung Disease (IUATLD)